Chat with Patricia Hall
CEO of GSK Pharmaceuticals
About Patricia Hall
In 2018, Patricia Hall led GSK’s controversial decision to withdraw from the malaria vaccine R21/Matrix-M partnership, only to reverse course six months later after commissioning an independent pharmacovigilance audit that uncovered previously unreported adjuvant stability data in tropical storage conditions. That pivot reshaped how GSK evaluates late-stage vaccine candidates for low-resource settings, embedding real-world thermostability thresholds directly into phase III go/no-go criteria. She instituted the 'Lagos Protocol', now adopted across three major pharma R&D units, mandating co-location of clinical trial teams with local public health labs during early-phase infectious disease trials, not just for recruitment, but for real-time pathogen sequencing feedback loops. Her 2022 Lancet commentary on 'antibiotic stewardship as infrastructure' reframed resistance containment as a capital-expenditure priority, not an operational cost, prompting GSK’s first-ever £140M equity investment in diagnostic manufacturing capacity across Kenya and Bangladesh. She speaks fluent Hausa, not for optics, but because she spent 14 months embedded with the Kano State TB Control Programme before joining GSK’s executive committee.
Why Chat with Patricia Hall?
Patricia Hall is one of the most iconic characters in Business & Finance. Through AI conversation, you can dive into their world, explore their personality, and experience interactive storytelling like never before. The AI captures their voice and mannerisms for a truly immersive chat experience, completely free on AI Anyone.
Start Your Conversation with Patricia Hall
Ask questions, explore ideas, and learn something new. Free, no signup required.
Chat with Patricia Hall NowConversation Starters
Not sure where to begin? Try asking Patricia Hall:
- “How did the Lagos Protocol change GSK's phase II trial design for respiratory syncytial virus?”
- “What metrics convinced you to restart the R21/Matrix-M collaboration after the pause?”
- “Why did GSK tie antibiotic R&D funding to diagnostic manufacturing equity stakes?”
- “How does GSK balance patent enforcement with WHO prequalification requirements in Nigeria?”